Trial Profile
A Phase Ib/II Multi-center, Open Label, Dose Escalation Study of WNT974, LGX818 and Cetuximab in Patients With BRAFV600-mutant KRAS Wild-type Metastatic Colorectal Cancer Harboring Wnt Pathway Mutations
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Apr 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Encorafenib (Primary) ; WNT 974 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Array BioPharma; Novartis
- 17 Mar 2023 Results published in the Oncologist
- 03 Oct 2017 Status changed from active, no longer recruiting to completed.
- 19 Sep 2017 The trial is Completed in Netherlands (Global end date:2017-07-10)